Second, we cannot determine if the SCD individuals are in the AD preclinical stage because of insufficient biomarker data, such as the cerebrospinal fluid (CSF) concentrations of hyperphosphorylated tau (p‐tau181p) and β‐amyloid (Aβ1‐42). Here, MAPT is linked to Alzheimer disease.